{"schema":"hottub-news/story/v1","story":"st_yxvhxiun2xlzcidbgada","title":"Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/phathom-pharmaceuticals-announces-initiation-of-registrational-phase-3-yxvhxiun2x","count":1,"items":[{"id":"n_yxvhxiun2xlzcidbgada","seq":663746,"kind":"press_release","title":"Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD","url":"https://www.globenewswire.com/news-release/2026/09/29/3370751/0/en/phathom-pharmaceuticals-announces-initiation-of-registrational-phase-3-study-of-voquezna-vonoprazan-for-as-needed-treatment-of-non-erosive-gerd.html","summary":"FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases, today announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of VOQUEZNA® (vonoprazan) tablets in adults with Non-Erosive…","published":"2026-09-29T12:00:00Z","seen":"2026-09-29T12:12:39Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:phat","us71722w1071"],"entities":[{"id":"Q223591","name":"gastroesophageal reflux disease","type":"other"}],"story":"st_yxvhxiun2xlzcidbgada","category":"health","category_p":0.6200000047683716,"sentiment":"neutral","tone":0.1599999964237213,"political":0.05999999865889549}]}